<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05062681</url>
  </required_header>
  <id_info>
    <org_study_id>Steroids in COVID-19</org_study_id>
    <nct_id>NCT05062681</nct_id>
  </id_info>
  <brief_title>RCT on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow</brief_title>
  <official_title>Randomized Controlled Trial on the Efficacy of Dexamethasone Versus Methyl Prednisolone in Covid-19 Infected Patients With High Oxygen Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the therapeutic activity and side effects of 16 mg/day&#xD;
      dexamethasone in comparison to equivalent dose of MP (1mg/kg/day)for the management of&#xD;
      COVID-19 infected patients.Moreover, and according to the importance of the IL-6/STAT-3 in&#xD;
      triggering the inflammatory cascade and as the miRNAs are considered as prognostic markers,&#xD;
      hence, the study aims also to study the impact of the used regimens on these biomarkers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>RANDOMIZED CONT</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>28 days in hospital mortality</measure>
    <time_frame>28 days</time_frame>
    <description>all patients who will die in 28 days from the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WHO clinical progression scale</measure>
    <time_frame>10 days</time_frame>
    <description>WHO clinical progression scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events related to steroids</measure>
    <time_frame>10 days</time_frame>
    <description>incidence of infection or hyperglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU stay</measure>
    <time_frame>10 days</time_frame>
    <description>Duration of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of high oxygen supplementation</measure>
    <time_frame>10 days</time_frame>
    <description>Duration of high oxygen supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>COVID-19 Pandemic</condition>
  <arm_group>
    <arm_group_label>Dexamethasone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive dexamethasone 8 mg q12hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methylprednisolone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Patients will receive dexamethasone 8 mg q12hours</description>
    <arm_group_label>Dexamethasone group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes</description>
    <arm_group_label>methylprednisolone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult (≥18 years of age) at time of enrolment&#xD;
&#xD;
          2. Present COVID-19 (infection confirmed by RT-PCR or antigen testing)&#xD;
&#xD;
          3. Postive pressure ventilation (non-invasive or invasive) or need supplemental oxygen&#xD;
             with non-rebreather mask&#xD;
&#xD;
          4. Admission to ICU in the last 24 hours&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1- Underlying disease requiring chronic corticosteroids 2- Any dose of dexamethasone&#xD;
             during the present hospital stay for COVID-19 for ≥5 days before enrollment 3-&#xD;
             Systemic corticosteroids during present hospital stay for conditions other than&#xD;
             COVID-19 (e.g. septic shock) 4-Any contraindication for corticosteroid administration&#xD;
             5-Cardiac arrest before ICU admission 6-Pregnancy or breast feeding 7-&#xD;
             Immunocompromised patients as cancer (active) patients, patients on chemotherapy or&#xD;
             radiotherapy, HIV, and transplant patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed EL-Ayashy, Ass. Professor</last_name>
    <role>Study Director</role>
    <affiliation>Ass. Professor of Anesthesia and Intensive Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Farouk Abdelsalam, Consultant</last_name>
    <role>Study Chair</role>
    <affiliation>Consultant of Clinical Pharmacy and Clinical Nutrition Al-Galaa Military Medical Complex (GMMC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eman Rostom, BSc</last_name>
    <phone>01111303366</phone>
    <email>eman.osama@std.pharma.cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dalaal Moustafa Abdallah, Professor</last_name>
    <phone>01222327743</phone>
    <email>dalaal.abdallah@pharma.cu.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eman Osama</name>
      <address>
        <city>Cairo</city>
        <zip>11757</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eman Osama</last_name>
      <phone>01111303366</phone>
      <email>eman.osama@std.pharma.cu.edu.eg</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648.</citation>
    <PMID>32091533</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Xie B, Hashimoto K. Current status of potential therapeutic candidates for the COVID-19 crisis. Brain Behav Immun. 2020 Jul;87:59-73. doi: 10.1016/j.bbi.2020.04.046. Epub 2020 Apr 22. Review.</citation>
    <PMID>32334062</PMID>
  </reference>
  <reference>
    <citation>Ye Q, Wang B, Mao J. The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19. J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10. Review.</citation>
    <PMID>32283152</PMID>
  </reference>
  <reference>
    <citation>Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001/jamainternmed.2020.0994. Erratum in: JAMA Intern Med. 2020 Jul 1;180(7):1031.</citation>
    <PMID>32167524</PMID>
  </reference>
  <reference>
    <citation>RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.</citation>
    <PMID>32678530</PMID>
  </reference>
  <reference>
    <citation>Villar J, Ferrando C, Martínez D, Ambrós A, Muñoz T, Soler JA, Aguilar G, Alba F, González-Higueras E, Conesa LA, Martín-Rodríguez C, Díaz-Domínguez FJ, Serna-Grande P, Rivas R, Ferreres J, Belda J, Capilla L, Tallet A, Añón JM, Fernández RL, González-Martín JM; dexamethasone in ARDS network. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020 Mar;8(3):267-276. doi: 10.1016/S2213-2600(19)30417-5. Epub 2020 Feb 7.</citation>
    <PMID>32043986</PMID>
  </reference>
  <reference>
    <citation>Meduri GU, Bridges L, Shih MC, Marik PE, Siemieniuk RAC, Kocak M. Prolonged glucocorticoid treatment is associated with improved ARDS outcomes: analysis of individual patients' data from four randomized trials and trial-level meta-analysis of the updated literature. Intensive Care Med. 2016 May;42(5):829-840. doi: 10.1007/s00134-015-4095-4. Epub 2015 Oct 27. Review.</citation>
    <PMID>26508525</PMID>
  </reference>
  <reference>
    <citation>Salton F, Confalonieri P, Meduri GU, Santus P, Harari S, Scala R, Lanini S, Vertui V, Oggionni T, Caminati A, Patruno V, Tamburrini M, Scartabellati A, Parati M, Villani M, Radovanovic D, Tomassetti S, Ravaglia C, Poletti V, Vianello A, Gaccione AT, Guidelli L, Raccanelli R, Lucernoni P, Lacedonia D, Foschino Barbaro MP, Centanni S, Mondoni M, Davì M, Fantin A, Cao X, Torelli L, Zucchetto A, Montico M, Casarin A, Romagnoli M, Gasparini S, Bonifazi M, D'Agaro P, Marcello A, Licastro D, Ruaro B, Volpe MC, Umberger R, Confalonieri M. Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia. Open Forum Infect Dis. 2020 Sep 12;7(10):ofaa421. doi: 10.1093/ofid/ofaa421. eCollection 2020 Oct.</citation>
    <PMID>33072814</PMID>
  </reference>
  <reference>
    <citation>Rana MA, Hashmi M, Qayyum A, Pervaiz R, Saleem M, Munir MF, Ullah Saif MM. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients. Cureus. 2020 Oct 12;12(10):e10918. doi: 10.7759/cureus.10918.</citation>
    <PMID>33194485</PMID>
  </reference>
  <reference>
    <citation>Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, Erfani A, Khodamoradi Z, Saadi MHG. Correction to: Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021 May 11;21(1):436. doi: 10.1186/s12879-021-06130-7.</citation>
    <PMID>33975548</PMID>
  </reference>
  <reference>
    <citation>Chen L, Lou J, Bai Y, Wang M. COVID-19 Disease With Positive Fecal and Negative Pharyngeal and Sputum Viral Tests. Am J Gastroenterol. 2020 May;115(5):790. doi: 10.14309/ajg.0000000000000610.</citation>
    <PMID>32205644</PMID>
  </reference>
  <reference>
    <citation>Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. Review.</citation>
    <PMID>19167326</PMID>
  </reference>
  <reference>
    <citation>Correia CN, Nalpas NC, McLoughlin KE, Browne JA, Gordon SV, MacHugh DE, Shaughnessy RG. Circulating microRNAs as Potential Biomarkers of Infectious Disease. Front Immunol. 2017 Feb 16;8:118. doi: 10.3389/fimmu.2017.00118. eCollection 2017. Review.</citation>
    <PMID>28261201</PMID>
  </reference>
  <reference>
    <citation>Guterres A, de Azeredo Lima CH, Miranda RL, Gadelha MR. What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19? Infect Genet Evol. 2020 Nov;85:104417. doi: 10.1016/j.meegid.2020.104417. Epub 2020 Jun 8.</citation>
    <PMID>32526370</PMID>
  </reference>
  <reference>
    <citation>Mirzaei R, Mahdavi F, Badrzadeh F, Hosseini-Fard SR, Heidary M, Jeda AS, Mohammadi T, Roshani M, Yousefimashouf R, Keyvani H, Darvishmotevalli M, Sani MZ, Karampoor S. The emerging role of microRNAs in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Int Immunopharmacol. 2021 Jan;90:107204. doi: 10.1016/j.intimp.2020.107204. Epub 2020 Nov 13. Review.</citation>
    <PMID>33221169</PMID>
  </reference>
  <reference>
    <citation>Abedi F, Rezaee R, Hayes AW, Nasiripour S, Karimi G. MicroRNAs and SARS-CoV-2 life cycle, pathogenesis, and mutations: biomarkers or therapeutic agents? Cell Cycle. 2021 Jan;20(2):143-153. doi: 10.1080/15384101.2020.1867792. Epub 2020 Dec 31. Review.</citation>
    <PMID>33382348</PMID>
  </reference>
  <reference>
    <citation>Abu-Izneid T, AlHajri N, Ibrahim AM, Javed MN, Salem KM, Pottoo FH, Kamal MA. Micro-RNAs in the regulation of immune response against SARS CoV-2 and other viral infections. J Adv Res. 2021 May;30:133-145. doi: 10.1016/j.jare.2020.11.013. Epub 2020 Dec 2. Review.</citation>
    <PMID>33282419</PMID>
  </reference>
  <reference>
    <citation>Li C, Hu X, Li L, Li JH. Differential microRNA expression in the peripheral blood from human patients with COVID-19. J Clin Lab Anal. 2020 Oct;34(10):e23590. doi: 10.1002/jcla.23590. Epub 2020 Sep 22.</citation>
    <PMID>32960473</PMID>
  </reference>
  <reference>
    <citation>Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, Zhang P, Liu X, Gao G, Liu F, Jiang Y, Cheng X, Zhu C, Xia Y. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infect. 2020 Dec;9(1):1123-1130. doi: 10.1080/22221751.2020.1770129.</citation>
    <PMID>32475230</PMID>
  </reference>
  <reference>
    <citation>Liu T, Zhang J, Yang Y, Ma H, Li Z, Zhang J, Cheng J, Zhang X, Zhao Y, Xia Z, Zhang L, Wu G, Yi J. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med. 2020 Jul 7;12(7):e12421. doi: 10.15252/emmm.202012421. Epub 2020 Jun 5.</citation>
    <PMID>32428990</PMID>
  </reference>
  <reference>
    <citation>Jafarzadeh A, Nemati M, Jafarzadeh S. Contribution of STAT3 to the pathogenesis of COVID-19. Microb Pathog. 2021 May;154:104836. doi: 10.1016/j.micpath.2021.104836. Epub 2021 Mar 7. Review.</citation>
    <PMID>33691172</PMID>
  </reference>
  <reference>
    <citation>Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, Avezum A, Lopes RD, Bueno FR, Silva MVAO, Baldassare FP, Costa ELV, Moura RAB, Honorato MO, Costa AN, Damiani LP, Lisboa T, Kawano-Dourado L, Zampieri FG, Olivato GB, Righy C, Amendola CP, Roepke RML, Freitas DHM, Forte DN, Freitas FGR, Fernandes CCF, Melro LMG, Junior GFS, Morais DC, Zung S, Machado FR, Azevedo LCP; COALITION COVID-19 Brazil III Investigators. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020 Oct 6;324(13):1307-1316. doi: 10.1001/jama.2020.17021.</citation>
    <PMID>32876695</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Eman Osama Zayed Mahmoud Rostom</investigator_full_name>
    <investigator_title>teaching assistant</investigator_title>
  </responsible_party>
  <keyword>steroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

